Steve Scala
Stock Analyst at TD Cowen
(2.79)
# 1,713
Out of 5,149 analysts
33
Total ratings
74.07%
Success rate
13.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Hold | $100 → $120 | $119.83 | +0.14% | 2 | Jan 20, 2026 | |
| RPRX Royalty Pharma | Maintains: Buy | $42 → $45 | $47.48 | -5.22% | 2 | Dec 11, 2025 | |
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $233.86 | -3.79% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $61.22 | -3.63% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $201.76 | -52.91% | 1 | Aug 12, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $26.58 | +20.39% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $1,007.73 | -50.38% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $164.18 | -36.05% | 4 | Feb 1, 2021 |
Merck & Co.
Jan 20, 2026
Maintains: Hold
Price Target: $100 → $120
Current: $119.83
Upside: +0.14%
Royalty Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $42 → $45
Current: $47.48
Upside: -5.22%
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $233.86
Upside: -3.79%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $61.22
Upside: -3.63%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $201.76
Upside: -52.91%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $26.58
Upside: +20.39%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $1,007.73
Upside: -50.38%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $164.18
Upside: -36.05%